You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

BRAF(V600) mutated

Showing 1 - 25 of 1,215
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Associated Factors, and Clinical Outcomes of Prescribing

Completed
  • BRAF v600 Mutated Metastatic Melanoma
    • East Hanover, New Jersey
      Novartis Pharmaceuticals
    Mar 28, 2023

    Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Tumor in the Brain, Metastatic Malignant Tumor in the CNS

    Recruiting
    • Clinical Stage IV Cutaneous Melanoma AJCC v8
    • +3 more
    • Scottsdale, Arizona
    • +2 more
    Jan 4, 2023

    BRAF V600-mutated Lung Carcinoma Treated With Combination of

    Completed
    • Non Small Cell Lung Cancer
    • BRAF V600 Mutation
      • CrĂ©teil, France
      • +1 more
      Jun 29, 2022

      Colorectal Cancer, Colon Cancer, BRAF V600E Trial (Binimetinib)

      Not yet recruiting
      • Colorectal Cancer
      • +4 more
      • (no location specified)
      Aug 18, 2022

      Malignant Melanoma, Brain Metastases Trial in Tucson (E6201, E6201 plus dabrafenib)

      Terminated
      Has Results
      • Malignant Melanoma
      • Brain Metastases
      • Tucson, Arizona
        University of Arizona Cancer Center
      Mar 5, 2022

      BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic Carcinoma Trial in Duarte, Columbus (Dabrafenib,

      Recruiting
      • BRAF NP_004324.2:p.V600E
      • +2 more
      • Duarte, California
      • +1 more
      Jan 19, 2023

      Colorectal Cancer Trial in Shanghai (VIC, Bevacizumab Plus Chemotherapy)

      Recruiting
      • Colorectal Cancer
      • VIC
      • Bevacizumab Plus Chemotherapy
      • Shanghai, China
        Department of General Surgery, Zhongshan Hospital, Fudan Univers
      Sep 14, 2022

      Non-small-cell Lung Cancer Trial (HL-085+Vemurafenib)

      Not yet recruiting
      • Non-small-cell Lung Cancer
      • (no location specified)
      Jun 8, 2023

      Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV Trial in Chicago

      Recruiting
      • Stage IV Colorectal Cancer Positive for BRAF V600E Mutation
      • +2 more
      • Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab
      • Chicago, Illinois
        Northwestern University
      Nov 16, 2022

      BRAF V600E Unresectable or Metastatic Melanoma, BRAF V600E Metastatic NSCLC, Melanoma Trial in Guangzhou (Encorafenib)

      Completed
      • BRAF V600E Unresectable or Metastatic Melanoma
      • +2 more
      • Guangzhou, Guangdong, China
        Sun Yat-sen University Cancer Center
      Jun 9, 2022

      Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma, Stage IIB Colon Cancer AJCC v8 Trial (drug, biological, procedure,

      Not yet recruiting
      • Colon Adenocarcinoma
      • +4 more
      • (no location specified)
      Jan 24, 2023

      Colorectal Cancer Trial in Shanghai (Vemurafenib, Cetuximab)

      Recruiting
      • Colorectal Cancer
      • Shanghai, Shanghai, China
        Shanghai Changzheng Hospital
      Aug 15, 2021

      Cancer Trial (Dabrafenib, Trametinib)

      Not yet recruiting
      • Cancer
      • (no location specified)
      May 25, 2023

      Aspirin in Combination With Trametinib and Dabrafenib

      Not yet recruiting
      • NSCLC
      • +4 more
      • Combind asprin with Trametinib and Dabrafenib
      • (no location specified)
      Aug 4, 2023

      NSCLC Trial in China, Taiwan (Encorafenib, Binimetinib)

      Recruiting
      • Non-Small Cell Lung Cancer
      • Beijing, China
      • +35 more
      Jun 29, 2022

      NSCLC, BRAF V600 Mutation, MET Exon 14 Mutation Trial in Guangzhou (Dabrafenib + Trametinib, Capmatinib)

      Not yet recruiting
      • NSCLC
      • +2 more
      • Guangzhou, Guangdong, China
        Cancer Center of Sun-Yat Sen University
      Sep 19, 2023

      Metastatic Colorectal Cancer, BRAF V600E Mutation Positive Trial in France (Collection of blood samples)

      Not yet recruiting
      • Metastatic Colorectal Cancer
      • BRAF V600E Mutation Positive
      • Collection of blood samples
      • Avignon, France
      • +26 more
      Nov 25, 2022

      Melanoma Trial in Boston, Harrison, New York (Dabrafenib, Trametinib, Phenformin)

      Active, not recruiting
      • Melanoma
      • Boston, Massachusetts
      • +2 more
      Jun 14, 2022

      Non Small Cell Lung Cancer Trial (HLX208+HLX10)

      Not yet recruiting
      • Non Small Cell Lung Cancer
      • HLX208+HLX10
      • (no location specified)
      Nov 30, 2022

      Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma Trial in United States (Dabrafenib Mesylate, Tazemetostat

      Recruiting
      • Clinical Stage IV Cutaneous Melanoma AJCC v8
      • Metastatic Melanoma
      • Dabrafenib Mesylate
      • +2 more
      • Atlanta, Georgia
      • +6 more
      Nov 30, 2022

      Cancer Trial in Worldwide (Dabrafenib, Trametinib)

      Completed
      • Cancer
      • Little Rock, Arkansas
      • +51 more
      Jun 8, 2022

      Colorectal Cancer, BRAF V600E Mutation Positive Trial (Encorafenib Oral Capsule + Cetuximab)

      Not yet recruiting
      • Colorectal Cancer
      • BRAF V600E Mutation Positive
      • Encorafenib Oral Capsule + Cetuximab
      • (no location specified)
      Jan 30, 2023

      Dabrafenib Plus Trametinib In Rare BRAF V600E Mutation-Positive

      Not yet recruiting
      • Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
      • Non-investigational
      • (no location specified)
      May 11, 2023

      Advanced Solid Tumor, BRAF V600 Mutation Trial in Nanchang, Jinan, Shanghai (ABM-1310)

      Not yet recruiting
      • Advanced Solid Tumor
      • BRAF V600 Mutation
      • Nanchang, Jiangxi, China
      • +2 more
      Aug 12, 2022

      Cancer, BRAF V600 Mutation, Melanoma Trial (XP-102, Trametinib)

      Not yet recruiting
      • Cancer
      • +5 more
      • (no location specified)
      Aug 18, 2022